PHARE: 6 Months versus 12 Months of Adjuvant Trastuzumab
Pivot X et al. PHARE trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. San Antonio Breast Cancer Symposium 2012;Abstract S5-3.
Dr Sledge is a Professor of Medicine and Chief of the Division of Oncology at Stanford University School of Medicine in Stanford, California.
|